-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 28,, Andesu released its 2016 semi-annual report, with operating income reaching RMB5,435 million, down 39% YoY; net profit attributable to shareholders of listed companies reached RMB1,102 million, up 109% YoY; and net profit attributable to shareholders of listed companies, net income attributable to non-recurring profit and loss, up 249% YoY7KA
Andesu products are divided into three categories: functional products (including methionine, vitamins, ammonium sulfate and sodium sulfate), specialty products (enzymes, transcancerous gastric protective methionine and organic selenium additives) and other products (disulfide, sulfuric acid and preparation processing services)7KA
Key performance drivers: 1, Andesu products are mainly in the animal feed nutrition additives market sales, the market is mainly driven by global consumption of meatIn this market, the Company mainly serves the poultry feed market, especially the methionine marketThis market size continues to grow each year as a result of increased consumption of poultry meat and continued industrialization of the poultry farming industry2, exchange rate impact: Andesu sales cover a large number of countries and regions, most of the dollar denominated, some in the euro or RMBIn terms of costs, Andesu's main plants are located in Europe and China, and most of the raw materials are purchased in euros, dollars or renminbi3, crude oil prices: Andesu used some of the raw materials are oil derivatives7KA
During the reporting period, the Company's performance continued to meet its expected target, mainly due to the following factors: lower crude oil prices due to the additional production capacity brought about by the completion of the nanjing plant phase II project to full production levels, lower crude oil prices, lower raw material costs helped by the strong dollar, and increased revenue from vitamin products, mainly due to higher sales prices and lower production costs7KA
Meanwhile, Alterion, a new probiotic product developed by the company and Novozymes, was launched during the reporting period Based on beneficial bacteria that increase feed conversion rates, the product provides poultry farms with a natural alternative to antibiotic growth agents 7KA July 28, Andesu released its 2016 semi-annual report, with operating income reaching RMB5,435 million, down 39% YoY; 7KA
Andesu products are divided into three categories: functional products (including methionine, vitamins, ammonium sulfate and sodium sulfate), specialty products (enzymes, transcancerous gastric protective methionine and organic selenium additives) and other products (disulfide, sulfuric acid and preparation processing services) 7KA
Key performance drivers: 1, Andesu products are mainly in the animal feed nutrition additives market sales, the market is mainly driven by global consumption of meat In this market, the Company mainly serves the poultry feed market, especially the methionine market This market size continues to grow each year as a result of increased consumption of poultry meat and continued industrialization of the poultry farming industry 2, exchange rate impact: Andesu sales cover a large number of countries and regions, most of the dollar denominated, some in the euro or RMB In terms of costs, Andesu's main plants are located in Europe and China, and most of the raw materials are purchased in euros, dollars or renminbi 3, crude oil prices: Andesu used some of the raw materials are oil derivatives 7KA
During the reporting period, the Company's performance continued to meet its expected target, mainly due to the following factors: lower crude oil prices due to the additional production capacity brought about by the completion of the nanjing plant phase II project to full production levels, lower crude oil prices, lower raw material costs helped by the strong dollar, and increased revenue from vitamin products, mainly due to higher sales prices and lower production costs 7KA
Meanwhile, Alterion, a new probiotic product developed by the company and Novozymes, was launched during the reporting period Based on beneficial bacteria that increase feed conversion rates, the product provides poultry farms with a natural alternative to antibiotic growth agents 7KA